Global Subdermal Contraceptive Implants Market

Subdermal Contraceptive Implants Market Outlook

The global Subdermal Contraceptive Implants market was valued at USD 966.4 Million in 2021 and is projected to reach USD 1,760.4 Million by 2029, expanding at a CAGR of 8.4% during the forecast period. The subdermal contraceptive implant is a small, flexible rod that is inserted under the skin of the inner upper arm. It slowly releases a progestogen hormone to prevent pregnancy for a long period of time which ranges from three to five years.

One of the common hormones used in contraceptive implants is progestogen, which is similar to the natural hormone progesterone that is synthesized by the female body. The implants are inserted subdermally, under local anesthesia with the use of a trocar, in the inner aspect of the non-dominant arm.

The implant works by preventing the release of the egg from the ovary (blocking the ovulation cycle) and restricts the entry of sperm to the uterus (womb) by thickening the cervical mucus.

Subdermal contraceptive implant is an effective method of birth control with a scientifically proven efficacy of more than 99% indicating that fewer than 1 in every 100 women using the implant method gets impregnated. Hence, it is one of the safest contraceptive option owing to the low failure rate. However, the effectiveness of subdermal contraceptive implant reduces due to the effect of other medications consumed simultaneously. These include some of the medicines used to treat HIV, epilepsy, tuberculosis (TB), and other high concentrate medicine.

A subdermal contraceptive implant has no serious side effects. Major side effects associated with the use of contraceptive implants are changes in frequency, duration, and amount of menstrual bleeding patterns. Some rare and minor side effects reported are infection at the site of the implant and ovarian cyst. All symptoms of side effects are temporary and fade out once the body gets metabolically adjusted to the implanted contraceptive device.

The continuation rate of subdermal contraceptive implant is higher, indicating continued use of the product after implanting it. According to research conducted by Cochrane Review, more than 80% of women continue the use their implant over two years of implantation. Various clinical trials and observational studies in a number of countries reported the continuation rates for implants to range between 78% to 96% at one year, and between 50% to 86% at three years.

Scope of Subdermal Contraceptive Implants Market Report

The report on the Subdermal Contraceptive Implants market includes an assessment of the market, size, share, trends, segments, and country markets. Overview and dynamics have been included in the report.

Attributes	Details
Report Title	Subdermal Contraceptive Implants Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast
Base Year	2021
Historic Data	2019 & 2020
Forecast Period	2022–2029
Segmentation	By Type (Jadelle, Sino-implant, Nexplanon), End user (Hospitals, Clinics, Others)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered	Merck & Co., Inc (Organon & Co.), Bayer AG, Shanghai Dahua Pharmaceutical Co., Ltd.

Subdermal Contraceptive Implants Market Dynamics

Rise in sexual and reproductive health awareness

Various countries are gearing up their awareness initiatives to address sexual and reproductive health issues with the vision to reduce pregnancy-related health disorders. Increase in awareness and proper guidance on contraceptives make adolescents more well informed of sexual safety.

The growing sex education in recent times has resulted not only in improvements in health-related outcomes such as reduced unintended pregnancies, high-risk pregnancies, maternal mortality, and infant mortality but also in improvements in schooling and economic outcomes, especially for girls and women. Hence, rise in sexual health awareness has widely promoted the use of subdermal contraceptive implants.

Long Term Contraceptive Solution

Subdermal Contraceptive Implants are used as effective long term contraceptive solution as it is meant for 3 to 5 years of use after its implantation in body. Women who use long-acting methods of birth control are less likely to wind up pregnant than women who use shorter-term methods, which require daily or monthly remembering. Long term contraceptives are 99% effective birth control solution (probability of getting pregnant even after the use of subdermal contraceptive implants is less than 1%) and thus the use of subdermal contraceptive implants is projected to grow over the forecast period.

Low Adaptability of Subdermal Contraceptive Implants Device

The adaptability of subdermal contraceptive implant is low as compared to other contraceptive options. In spite of healthcare infrastructure development, and its awareness in family planning programs around the globe, contraceptive implants are not used as primary contraceptive method. This can be attributed to low availability of the device and sophisticated implantation surgeries which is mandatorily done by medical professionals. Hence, the use of subdermal contraceptive implants device is low in the regions where availability of other contraceptives such as oral pills are prevalent.

Comparatively Fewer Side Effects with High Efficacy

Subdermal Contraceptive Implants have comparatively lesser side effects than other contraceptives option. Potential side effects include headaches, abdominal pain, weight gain, nausea, mood swings, dizziness, acne, and breast tenderness. However, side effects reported after the use of subdermal contraceptive implants are minimal, remain prevalent until body gets used to the implant and usually fade away after a few months.

Rarely, the side effects are serious. Hence, as subdermal contraceptive implants is regarded one of the safest contraceptive method compared to other alternatives, and its prevalence is expected to rise over the forecast period.

Subdermal Contraceptive Implants Market Segmental Outlook

Based on type, the subdermal contraceptive implants market is segmented into jadelle, sino-implant, and nexplanon. Jadelle is expected to hold a significant share in subdermal contraceptive implants market during the forecast period as it effective and reversible contraceptive that inhibits pregnancy up to 5 years. It is one of the most effective implant contraception available in the market. Sino-implant segment is expected to expand at rapid growth rate during the forecast period.

Sino-implant is prequalified for maximum 3 years of use with shell life of 4 years. Its accuracy rate is 99% which indicates that fewer than 1 pregnancy per 100 users is reported. Sino-implant has been registered by more than 20 drug regulatory authorities worldwide. Nexplanon segment is projected to grow at a rapid pace during the forecast period as it is a hormone-releasing birth control implant to prevent pregnancy for up to 3 years.

It steadily releases a small dose of the hormone progestogen into users bloodstream which prevents the egg from being released from the ovary, and thickens cervical mucous to prevent sperm from reaching an egg.

Based on end-users, the subdermal contraceptive implants market is classified as hospitals, clinics, and others. The hospitals segment is expected to hold a significant share of the subdermal contraceptive implants market during the forecast period, as the insertion of contraceptives under the arm skin cannot be legally performed by patients and require professional medical practitioners to safely install the device.

The clinics segment is expected to expand at rapid growth rate during the forecast period. The patient is required to visit clinics to implant subdermal contraceptives, especially in undeveloped and developing regions due to less number of hospitals. The others segment is projected to grow at a steady pace during the forecast period.

The segment include ambulatory surgical centers, research centers, and medical institutions. The demand for subdermal contraceptive implants from various other end-users is increasing owing to growing R&D activities and technological advancements in the contraceptive medical device industry.

Subdermal Contraceptive Implants Market Regional Outlook

Based on the regions, the Global Subdermal Contraceptive Implants Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The Middle East & Africa region is projected to account significant market share and is anticipated to dominate the global market in coming years owing to increasing preference for implantable contraceptives over traditional methods. Moreover, their cost-effectiveness, long-term contraceptive solution, and low risk of pelvic inflammatory disease are expected to fuel the market in the region. Increasing adoption of subdermal contraceptive implants due to the surging population and rising cases of unwanted pregnancies is expected to propel the market in Asia Pacific during the forecast period.

North America holds a major share in the global subdermal contraceptive implant market, owing to increasing technological development in contraceptive science in the region. The market in the region is projected to grow, as the female population is adopting modern methods of contraception such as subdermal contraceptive implant, as they are safe and offer high efficacy.

The market in Europe is anticipated to grow at a substantial pace in the coming years, despite the low fertility rate in Europe owing to high awareness about contemporary contraception, presence of well-established healthcare infrastructure, and priority to safe and effective contraceptive methods.

Key Benefits for Industry Participants & Stakeholders

• In-depth Analysis of the Global Subdermal Contraceptive Implants Market
• Historical, Current, and Projected Market Size in terms of Value.
• Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
• Industry Drivers, Restraints, and Opportunities Covered in the Study
• Recent Industry Trends and Developments
• Competitive Landscape & Strategies of Key Players
• Neutral Perspective on Global Subdermal Contraceptive Implants Market Performance

Segments

By Type

• Jadelle
• Sino-implant
• Nexplanon

By End user

• Hospitals
• Clinics
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Market Players Profiled in the Report

• Merck & Co., Inc (Organon & Co.)
• Bayer AG
• Shanghai Dahua Pharmaceutical Co., Ltd

Competitive Landscape

• Top players in the market include Merck & Co., Inc (Organon & Co.), Bayer AG, and Shanghai Dahua Pharmaceutical Co., Ltd. These companies are considered key manufacturers of Subdermal Contraceptive Implants based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
• The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunities for the Subdermal Contraceptive Implants market.